DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report report published on Sunday. The firm issued a hold rating on the stock.

DBVT has been the subject of a number of other research reports. HC Wainwright reiterated a buy rating and issued a $5.00 price target on shares of DBV Technologies in a research note on Thursday, August 1st. JMP Securities reissued a market outperform rating and issued a $5.00 price objective on shares of DBV Technologies in a research report on Tuesday, September 24th.

DBV Technologies Price Performance

Shares of DBVT stock opened at $0.70 on Friday. The stock has a market cap of $67.55 million, a P/E ratio of -0.83 and a beta of 0.67. The company has a fifty day moving average price of $0.80 and a two-hundred day moving average price of $0.99. DBV Technologies has a one year low of $0.50 and a one year high of $2.40.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same quarter in the prior year, the business earned ($0.26) EPS. As a group, equities research analysts anticipate that DBV Technologies will post -1.43 EPS for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. grew its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.